Article
Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Frontiers in immunology - 1 Jan 2023
Li Mengyuan, Gao Xuejiao, Wang Xiaosheng
Abstract excerpt
Background: Tumor mutation burden (TMB) has been recognized as a predictive biomarker for immunotherapy response in cancer. Systematic identification of molecular features correlated with TMB is significant, although such investigation remains insufficient. Methods: We analyzed associations of somatic mutations, pathways, protein expression, microRNAs (miRNAs), long non-coding RNAs (lncRNAs), competing endogenous...
Topics
Join the communities discussing this publication.